SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Fancy who wrote (4767)7/6/1998 11:29:00 PM
From: Bhag Karamchandani  Read Replies (2) of 6136
 
Steve: Thanks for the detailed post. The following statement is puzzling:
"Anticipated Milestones"
AG3340 Initiate Phase I trial in acute macular degeneration - 3Q98"
The above ignores AG3340 Phase II/III cancer trials. Is this an oversight or is it based on something they know and which some of us have feared: the projected PIII outcome - to the degree it can be projected by non experts- based on PI results.

I continue to believe that new drugs will increasingly start to emulate life cycles resembling those of technology products- just look at anti cholesterol, stroke, and angina line ups. The only difference is that the product (drug) replacement rather than upgrades will be the norm and hence the cause for fluctuating fortunes of smaller companies such as AGPH.

Each AIDS conference, with built in bias on the part of research scientists to hype or at least promote their research, result in the caveats being ignored, and casts a shadow on AGPH fortunes since they are tied to AIDS and AIDS alone. And unfortunately for AIDS sufferers and AGPH there is no single drug to control the disease. AGPH must diversify. Recent moves constitute concentration not dispersion of investor risk.

Q: Is Remune specifically limited to potential application for AIDS treatment . Any experts out there with answers??

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News